| Name | Title | Contact Details |
|---|
Mold Law Groups litigation platform is a culmination of over 15 years of in-depth research by environmentalists, epidemiologists, toxicologists, medical professionals, Neurotoxicologists, Neuropsychologists, and law firms. Our proven methodology, for the first time, provides litigators the ability to couple the human pathogens in an environment to the direct causation of disease within the human body. The development of this cutting-edge science required an understanding of many different scientific disciplines and medical philosophies to provide a unique and new model for mold litigation. This platform is designed to defend or prosecute property and medical damages caused by mold and microbial exposure. Using precision based DNA-PCR sequencing, bacteria culturing, endotoxin testing, (1—>3)β-D beta glucan and other advanced environmental and medical testing, we leverage cutting edge technology and advanced mold litigation techniques to provide our clients with unparalleled and detailed services found nowhere else in our industry. Mold Law Group offers expert witnesses, consulting services, medical resources, legal resources, and environmental resources. We offer these services nationally and internationally. Mold Law Group is the absolute gold standard when it comes to mold litigation consulting.
Yokogawa Electric Corporation is a global leader in measurement, control, and information technologies. Founded in 1915 in Tokyo, Japan, the company began as a small laboratory focused on producing instruments that were primarily imported at the time. Today, Yokogawa operates in 60 countries and employs over 17,365 people, with a significant presence in North America. The company offers a diverse range of products and services, including measurement instruments, advanced control solutions for industrial automation, and information technologies for data management and analysis. Yokogawa serves various industries such as energy, chemicals, pharmaceuticals, and food, helping clients tackle complex production and operations management challenges. Their commitment to quality, innovation, and societal contribution guides their operations and partnerships with customers.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.